Accesso libero

In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]

Simona Kranjc

Simona Kranjc

Institute of Oncology Ljubljana, Department of Experimental OncologyLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Kranjc, Simona
, 
Maja Cemazar

Maja Cemazar

  • Institute of Oncology Ljubljana, Department of Experimental OncologyLjubljana, Slovenia
  • University of Primorska, Faculty of Health SciencesIzola, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Cemazar, Maja
, 
Gregor Sersa

Gregor Sersa

  • Institute of Oncology Ljubljana, Department of Experimental OncologyLjubljana, Slovenia
  • Faculty of Health Sciences, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Sersa, Gregor
, 
Janez Scancar

Janez Scancar

Department of Environmental Sciences, Jozef Stefan InstituteLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Scancar, Janez
 e 
Sabina Grabner

Sabina Grabner

Faculty of Chemistry and Chemical Technology, University of LjubljanaLjubljana, Slovenia
Cerca questo autore su
Sciendo|Google Scholar
Grabner, Sabina
  
14 set 2017
In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]'s Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Scarica la copertina
Categoria dell'articolo: Research Article
Pubblicato online: 14 set 2017
Pagine: 295 - 306
Ricevuto: 20 lug 2017
Accettato: 04 ago 2017
DOI: https://doi.org/10.1515/raon-2017-0034
Parole chiave
© 2017 Simona Kranjc, Maja Cemazar, Gregor Sersa, Janez Scancar, Sabina Grabner
This work is licensed under the Creative Commons Attribution 4.0 International License.

Background

Cisplatin is used in cancer therapy, but its side effects and acquired resistance to cisplatin have led to the synthesis and evaluation of new platinum compounds. Recently, the synthesized platinum compound trans-[PtCl2(3-Hmpy)2] (3-Hmpy = 3-hydroxymethylpyridine) (compound 2) showed a considerable cytotoxic and antitumour effectiveness. To improve compound 2 cytotoxicity in vitro and antitumour effectiveness in vivo, electroporation was used as drug delivery approach to increase membrane permeability (electrochemotherapy).

Materials and methods

In vitro, survival of sarcoma cells with different intrinsic sensitivity to cisplatin (TBLCl2 sensitive, TBLCl2Pt resistant and SA-1 moderately sensitive) was determined using a clonogenic assay after treatment with compound 2 or cisplatin electrochemotherapy. In vivo, the antitumour effectiveness of electrochemotherapy with compound 2 or cisplatin was evaluated using a tumour growth delay assay. In addition, platinum in the serum, tumours and platinum bound to the DNA in the cells were performed using inductively coupled plasma mass spectrometry.

Results

In vitro, cell survival after treatment with compound 2 electrochemotherapy was significantly decreased in all tested sarcoma cells with different intrinsic sensitivity to cisplatin (TBLCl2 sensitive, TBLCl2Pt resistant and SA-1 moderately sensitive). However, this effect was less pronounced compared to cisplatin. Interestingly, the enhancement factor (5-fold) of compound 2 cytotoxicity was equal in cisplatin-sensitive TBLCl2 and cisplatin-resistant TBLCl2Pt cells. In vivo, the growth delay of subcutaneous tumours after treatment with compound 2 electrochemotherapy was lower compared to cisplatin. The highest antitumour effectiveness after cisplatin or compound 2 electrochemotherapy was obtained in TBLCl2 tumours, resulting in 67% and 11% of tumour cures, respectively. Compound 2 induced significantly smaller loss of animal body weight compared to cisplatin. Furthermore, platinum amounts in tumours after compound 2 or cisplatin electrochemotherapy were approximately 2-fold higher compared to the drug treatment only, and the same increase of platinum bound to DNA was observed.

Conclusions

The obtained results in vitro and in vivo suggest compound 2 as a potential antitumour agent in electrochemotherapy.
Lingua:
Inglese
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicina, Medicina clinica, Medicina interna, Ematologia, Oncologia, Radiologia
Feed RSS della rivista